Related Experiment Video

Updated: Jun 28, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Selected markers of ovarian cancer and their relation to targeted therapy (Review)

Anna Markowska1, Zbigniew Kojs2, Damian Twardawa3

  • 1Department of Perinatology and Women's Diseases, Poznan University of Medical Sciences, 60-535 Poznan, Poland.

Experimental and Therapeutic Medicine
|April 17, 2024
PubMed

Insights

New molecular markers and targeted therapies show promise for improving ovarian cancer survival. Research explores novel biomarkers and drugs targeting cancer stem cells and immune responses to combat chemoresistance and recurrence.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Ovarian cancer (OC) survival rates remain low despite advances in surgery and chemotherapy.
  • Late-stage diagnosis, chemoresistance, and recurrence are major challenges in OC treatment.

Purpose of the Study:

  • To review emerging molecular markers and targeted therapies for ovarian cancer.
  • To discuss novel therapeutic strategies including targeting cancer stem cells and developing vaccines.

Main Methods:

  • Literature review of experimental research on molecular markers and therapeutic agents.
  • Analysis of potential drug targets such as angiopoietin-2, ectonucleotide pyrophosphatase/phosphodiesterase 1, E-cadherin, TIMP metallopeptidase inhibitor 1, and Kruppel-like factor 7.
  • Discussion of drugs affecting cancer stem cells (CSCs) and CSC markers like aldehyde dehydrogenase 1 and Nanog homeobox.

Main Results:

  • Identified several novel molecular markers with potential for targeted ovarian cancer therapy.
  • Highlighted drugs like metformin and salinomycin that target CSCs.
  • Explored the potential of ATRA and microRNA in inhibiting CSC markers.
  • Described a novel vaccine approach using CD117(+) and CD44(+) stem cells.

Conclusions:

  • Emerging molecular markers and targeted therapies offer new avenues for ovarian cancer treatment.
  • Targeting cancer stem cells and exploring novel vaccine strategies represent promising future directions.
  • Further research is needed to translate these experimental findings into clinical applications for improved ovarian cancer outcomes.
Keywords:
E-cadherinKruppel like factor 7Nanog homeoboxTIMP metallopeptidase inhibitor 1aldehyde dehydrogenase 1 family member A1angiopoietin-2cancer stem cellsectonucleotide pyrophosphatase/phosphodiesterase 1endothelial cell-specific molecule 1markersovarian cancersodium-dependent phosphate transport protein 2Bvaccines containing CSCs

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.7K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K